



See Below for Embargo Dates

Pfizer Oncology Data Presentations at ASCO 2010

At the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting, Pfizer Oncology will present the following data:

Crizotinib (PF-02341066):

(Abstract # 3) ASCO Plenary Session: Clinical activity of the oral ALK inhibitor PF-02341066 in ALK positive patients with non-small cell lung cancer (NSCLC). Yung- Jue Bang. Sunday, June 6. Session Time: 1:00pm – 4:00pm. Presentation Time: 2:30pm, N Hall B1. *(Embargoed until Saturday, June 5, 2010 at 9:00am EST)*

(Abstract # 2596) General Poster Session: Pharmacokinetics of PF-02341066, a dual ALK/MET inhibitor after multiple oral doses to advanced cancer patients. Weiwei Tan. Monday, June 7. Session Time: 8:00am - 12:00pm, S Hall A2. *(Embargoed until Thursday, May 20, 2010 at 6:00pm EST)*

PF-00299804:

(Abstract # LBA7523) Poster Discussion Session: Efficacy and safety of PF299804 versus erlotinib: A global, randomized Phase 2 trial in patients with advanced non-small cell lung cancer (NSCLC) after failure of chemotherapy. Michael J. Boyer. Monday, June 7. Session Time: 8:00am - 12:00pm, E450b. Discussion Time: 12:00pm - 1:00pm, E Hall D1. *(Embargoed until Saturday, June 5, 2010 at 8:00am EST)*

(Abstract # 5531) Poster Discussion Session: Phase 2 trial of the irreversible oral pan-HER inhibitor PF-00299804 as first-line treatment in recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). Christophe Le Tourneau. Friday, June 4. Session Time: 2:00pm - 6:00pm, S403. Discussion Time: 5:00 – 6:00pm, S406 (Vista Room). *(Embargoed until Thursday, May 20, 2010 at 6:00pm EST)*

(Abstract # 3026) Poster Discussion Session: Phase 1 study of PF-00299804 combined with figitumumab (CP-751,871) in patients with advanced solid tumors (ASTs). Emiliano Calvo. Sunday, June 6. Session Time: 2:00pm - 6:00pm, E450b. Discussion Time: 5:00pm - 6:00pm, E Hall D2. *(Embargoed until Thursday, May 20, 2010 at 6:00pm EST)*

(Abstract # 7596) General Poster Session: PF-00299804 (PF299) patient-reported outcomes (PROs) and efficacy in adenocarcinoma (adeno) and nonadeno non-small cell lung cancer (NSCLC): A Phase 2 trial in advanced NSCLC after failure of chemotherapy and erlotinib. Alicyn Campbell. Sunday, June 6. Session Time: 8:00am - 12:00pm, S Hall A2. *(Embargoed until Thursday, May 20, 2010 at 6:00pm EST)*

(Abstract # 7599) General Poster Session: PF-00299804 (PF299) in Asian patients with non-small cell lung cancer (NSCLC) refractory to chemotherapy and erlotinib or gefitinib: A Phase 1/2 study. Keunchil Park. Sunday, June 6. Session Time: 8:00am - 12:00pm, S Hall A2. *(Embargoed until Thursday, May 20, 2010 at 6:00pm EST)*

(Abstract # 7537) General Poster Session: Efficacy and safety of PF-00299804 (PF299), an oral, irreversible, pan-human epidermal growth factor receptor (pan-HER) tyrosine kinase inhibitor (TKI), as first-line treatment of selected patients with advanced non-small cell lung cancer (NSCLC). Tony Mok. Sunday, June 6. Session Time: 8:00am - 12:00pm, S Hall A2. *(Embargoed until Thursday, May 20, 2010 at 6:00pm EST)*

See Below for Embargo Dates

Bosutinib:

(Abstract # 6502) Oral Presentation: Safety and efficacy of bosutinib (SKI-606) in patients with chronic phase (CP) chronic myeloid leukemia (CML) following resistance or intolerance to imatinib. Jorge E. Cortes. Monday, June 7. Session Time: 9:30am -12:30pm. Presentation Time: 10:00am, E354b. *(Embargoed until Thursday, May 20, 2010 at 6:00pm EST)*

(Abstract # 6509) Poster Discussion Session: Safety and efficacy of bosutinib in patients with AP and BP CML and ph+ ALL following resistance/intolerance to imatinib and other TKIs: Update from study SKI-200. Carlo Gambacorti-Passerini. Monday, June 7. Session Time: 2:00pm - 6:00pm, E450a. Discussion Time: 5:00pm - 6:00pm, E354a. *(Embargoed until Thursday, May 20, 2010 at 6:00pm EST)*

(Abstract # 6514) Poster Discussion Session: Safety and efficacy of third-line bosutinib in imatinib and dasatinib resistant or intolerant chronic phase (CP) chronic myeloid leukemia (CML). Hanna Jean Khoury. Monday, June 7. Session Time: 2:00pm - 6:00pm, E450a. Discussion Time: 5:00pm - 6:00pm, E354a. *(Embargoed until Thursday, May 20, 2010 at 6:00pm EST)*

Pfizer/Genomic Health Partnership:

(Abstract # 4501) Clinical Science Symposium: Identification of prognostic genomic markers in patients with localized clear cell renal cell carcinoma (ccRCC). Brian I. Rini. Saturday, June 5. Session Time: 8:00am - 9:30am. Presentation Time: 8:15am, E Hall D2. *(Embargoed until Thursday, May 20, 2010 at 6:00pm EST)*

Sunitinib:

(Abstract # 4000) Clinical Science Symposium: Updated safety and efficacy results of the Phase 3 trial of sunitinib versus placebo for treatment of pancreatic neuroendocrine tumors (NET). Patricia Niccoli. Saturday, June 5. Session Time: 1:15pm - 2:45pm. Presentation Time: 1:15pm, N Hall B1. *(Embargoed until Thursday, May 20, 2010 at 6:00pm EST)*

(Abstract # 4003) Clinical Science Symposium: Patient-reported outcomes (PROs) in patients with pancreatic neuroendocrine tumors (NET) receiving sunitinib in a Phase 3 trial. Aaron Vinik. Saturday, June 5. Session Time: 1:15pm - 2:45pm. Presentation Time: 2:15pm, N Hall B1. *(Embargoed until Thursday, May 20, 2010 at 6:00pm EST)*

(Abstract # 4031) Poster Discussion Session: Cox proportional hazard analysis of sunitinib efficacy across subgroups of patients with progressive pancreatic neuroendocrine tumors (NET). Eric Raymond. Friday, June 4. Session Time: 2:00pm - 6:00pm, E450b. Discussion Time: 5:00pm - 6:00pm, E354a. *(Embargoed until Thursday, May 20, 2010 at 6:00pm EST)*

(Abstract # LBA1010) Oral Presentation: Sunitinib in combination with docetaxel vs docetaxel alone for the first-line treatment of advanced breast cancer. Jonas Bergh. Tuesday, June 8. Session Time: 9:30am - 12:30pm. Presentation Time: 10:00am, E Hall D1. *(Embargoed until Saturday, June 5, 2010 at 8:00am EST)*

See Below for Embargo Dates

(Abstract # LBA1011) Oral Presentation: Phase 3 trial of sunitinib in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC). John Crown. Tuesday, June 8. Session Time: 9:30am - 12:30pm. Presentation Time: 10:15am, E Hall D1. *(Embargoed until Saturday, June 5, 2010 at 8:00am EST)*

(Abstract # 6009) Poster Discussion Session: Burden of illness estimates of metastatic breast cancer (MBC) in the United States. Sonja Sorensen. Saturday, June 5. Session Time: 8:00am - 12:00pm, S403. Discussion Time: 12:00pm - 1:00pm, S504. *(Embargoed until Thursday, May 20, 2010 at 6:00pm EST)*

(Abstract # 3532) Poster Discussion Session: A randomized, Phase 2b study of sunitinib plus 5-fluorouracil, leucovorin and oxaliplatin (mFOLFOX6) versus bevacizumab plus mFOLFOX6 as first-line treatment for metastatic colorectal cancer (mCRC): Interim results. J. Randolph Hecht. Tuesday, June 8. Session Time: 8:00am - 12:00pm, S403. Discussion Time: 11:00am - 12:00pm, S406 (Vista Room). *(Embargoed until Thursday, May 20, 2010 at 6:00pm EST)*

(Abstract # 7581) General Poster Session: Phase 2 study of sunitinib in patients with non-small cell lung cancer (NSCLC) and irradiated brain metastases: Final efficacy and safety results. Silvia Novello. Sunday, June 6. Session Time: 8:00am - 12:00pm, S Hall A2. *(Embargoed until Thursday, May 20, 2010 at 6:00pm EST)*

(Abstract # 1055) General Poster Session: Correlations between efficacy and early changes in biomarkers in a metastatic breast cancer (mBC) clinical trial with sunitinib malate. Kiana Keyvanjah. Saturday, June 5. Session Time: 2:00pm - 6:00pm, S Hall A2. *(Embargoed until Thursday, May 20, 2010 at 6:00pm EST)*

(Abstract # 4594) General Poster Session: TWiST analysis to estimate overall benefit for metastatic renal cell carcinoma (mRCC) patients treated in a Phase 3 trial of sunitinib versus interferon-alfa (IFN-a). Sujata Patil. Monday, June 7. Session Time: 1:00pm - 5:00pm, S Hall A2. *(Embargoed until Thursday, May 20, 2010 at 6:00pm EST)*

(Abstract # 10059) General Poster Session: Sunitinib-related hypertension in a randomized placebo-controlled trial of GIST patients. Michael Ewer. Sunday, June 6. Session Time: 2:00pm - 6:00pm, S Hall A2. *(Embargoed until Thursday, May 20, 2010 at 6:00pm EST)*

Figitumumab:

(Abstract # 7500) Clinical Science Symposium: Randomized, open label, Phase 3 trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC). Jacek Jassem. Saturday, June 5. Session Time: 8:00am – 9:30am. Presentation Time: 8:00am, E Hall D1. *(Embargoed until Thursday, May 20, 2010 at 6:00pm EST)*

Axitinib:

(Abstract # TPS235) Trials in Progress Poster Session: Axitinib with or without dose titration as first-line therapy for metastatic renal cell carcinoma (mRCC). Eric Jonasch. Monday, June 7. Session Time: 8:00am - 12:00pm, S Hall A2. *(Embargoed until Thursday, May 20, 2010 at 6:00pm EST)*

See Below for Embargo Dates

(Abstract # 6136) General Poster Session: Can patient-reported kidney cancer-specific symptoms at baseline serve as an indicator for median progression-free and overall survival in sorafenib-refractory metastatic renal cell carcinoma? Peter C Trask. Monday, June 7. Session Time: 1:00pm – 5:00pm, S Hall A2. *(Embargoed until Thursday, May 20, 2010 at 6:00pm EST)*

Temsirolimus:

(Abstract # 9541) Poster Discussion Session: Phase 2 study of temsirolimus in children with high-grade glioma, neuroblastoma, and rhabdomyosarcoma. Birgit Georger. Sunday, June 6. Session Time: 2:00pm - 6:00pm, S Hall A2. Discussion Time: 5:00pm - 6:00pm, S504. *(Embargoed until Thursday, May 20, 2010 at 6:00pm EST)*

(Abstract # 4631) General Poster Session: Serum lactate dehydrogenase (LDH) as a biomarker for survival with mTOR inhibition in patients with metastatic renal cell carcinoma (RCC). Andrew J. Armstrong. Session Time: 1:00pm - 5:00pm, S Hall A2. *(Embargoed until Thursday, May 20, 2010 at 6:00pm EST)*

CDX-110:

(Abstract # 2014) Poster Discussion Session: Interim Data for ACT III: Phase 2 trial of PF-04948568 (CDX-110) in combination with temozolomide in patients with glioblastoma (GBM). Rose Lai. Saturday, June 5. Session Time: 8:00am – 12:00pm, S103. Discussion Time: 12:00pm – 1:00pm, S100b. *(Embargoed until Thursday, May 20, 2010 at 6:00pm EST)*

Tremelimumab:

(Abstract # 4134) General Poster Session: A Phase 1 dose escalation trial of CP-675206 (tremelimumab) in combination with gemcitabine in patients with chemotherapy-naive metastatic pancreatic cancer. Massimo Aglietta. Sunday, June 6. Session Time: 2:00pm - 6:00pm, S Hall A2. *(Embargoed until Thursday, May 20, 2010 at 6:00pm EST)*

(Abstract # 2574) General Poster Session: Clinical outcome of first-line melanoma patients who continue tremelimumab in spite of early disease progression. Diane I. Healey. Monday, June 7. Session Time: 8:00am - 12:00pm, S Hall A2. *(Embargoed until Thursday, May 20, 2010 at 6:00pm EST)*

(Abstract # 2609) General Poster Session: Evaluation of baseline serum C-reactive protein (CRP) and benefit from tremelimumab compared to chemotherapy in first-line melanoma. Margaret A. Marshall. Monday, June 7. Session Time: 8:00am - 12:00pm, S Hall A2. *(Embargoed until Thursday, May 20, 2010 at 6:00pm EST)*

Early Development Compounds:

(Abstract # 3028) Poster Discussion Session: Final report of Phase 1 clinical, pharmacokinetic, pharmacodynamic study of PF-00562271 targeting focal adhesion kinase (FAK) in patients with solid tumors. Neesha C. Dhani. Sunday, June 6. Session Time: 2:00pm - 6:00pm, E450b. Discussion Time: 5:00pm - 6:00pm, E Hall D2. *(Embargoed until Thursday, May 20, 2010 at 6:00pm EST)*

See Below for Embargo Dates

(Abstract # 2524) Poster Discussion Session: First-in-human dose-escalation safety and PK trial of a novel intravenous humanized monoclonal CovX body inhibiting angiopoietin 2. Lee S. Rosen. Saturday, June 5. Session Time: 8:00am - 12:00pm, E450a. Discussion Time: 12:00pm – 1:00pm, E354b. *(Embargoed until Thursday, May 20, 2010 at 6:00pm EST)*

(Abstract # 3033) Poster Discussion Session: Pharmacodynamically guided dose selection of PF-00337210, a VEGFR2 tyrosine kinase inhibitor, in a Phase 1 study. Glenn Liu. Sunday, June 6. Session Time: 2:00pm - 6:00pm, E450b. Discussion Time: 5:00pm - 6:00pm, E Hall D2. *(Embargoed until Thursday, May 20, 2010 at 6:00pm EST)*

(Abstract # 3062) General Poster Session: Phase 1 clinical trial of gemcitabine in combination with PF-00477736 (PF-736) a selective inhibitor of CHK1 kinase. Nicoletta Brega. Monday, June 7. Session Time: 8:00am -12:00pm, S Hall A2. *(Embargoed until Thursday, May 20, 2010 at 6:00pm EST)*

(Abstract # 3060) General Poster Session: Phase 1 study of PD 0332991, cyclin-D kinase (CDK) 4/6 inhibitor in combination with letrozole for first-line treatment of patients with ER-positive, HER2-negative breast cancer. Dennis J. Slamon. Monday, June 7. Session Time: 8:00am - 12:00pm, S Hall A2. *(Embargoed until Thursday, May 20, 2010 at 6:00pm EST)*

(Abstract # 3034) General Poster Session: Phase 1 study of PF-03446962, a fully human mab against ALK 1, a TGF-beta receptor involved in tumor angiogenesis. Laura Williams Goff. Monday, June 7. Session Time: 8:00am - 12:00pm, S Hall A2. *(Embargoed until Thursday, May 20, 2010 at 6:00pm EST)*

(Abstract # 2539) General Poster Session: A Phase 1 study of CD40 agonist monoclonal antibody (CP-870,893) with gemcitabine in pancreatic cancer. Gregory Lawrence Beatty. Monday, June 7. Session Time: 8:00am - 12:00pm, S Hall A2. *(Embargoed until Thursday, May 20, 2010 at 6:00pm EST)*

###